Genscript Biotech (STU:G51) Marketable Securities: €532.9 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:G51 Genscript Biotech Corp STU:G51
77 GF Score
Price €3.18
GF Value €1.97
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Genscript Biotech Marketable Securities?

Genscript Biotech STU:G51 +3.92% 77 Marketable Securities is €532.9 Mil as of Jun. 2026. GuruFocus rates STU:G51 with a GF Score™ of 77/100 and a GF Value™ of €1.97 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Genscript Biotech's Marketable Securities for the quarter that ended in Jun. 2026 was €532.9 Mil.

Genscript Biotech's annual Marketable Securities increased from Dec. 2023 (€441.7 Mil) to Dec. 2024 (€467.2 Mil) and increased from Dec. 2024 (€467.2 Mil) to Dec. 2025 (€571.8 Mil).

Genscript Biotech  (STU:G51) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Genscript Biotech Marketable Securities Related Terms

Genscript Biotech Marketable Securities Historical Data

* Premium members only.

The historical data trend for Genscript Biotech's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genscript Biotech Marketable Securities Chart

Genscript Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 196.68 414.73 441.67 467.18 571.76

Genscript Biotech Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,369.94 467.18 559.35 571.76 532.87
STU:G51
77GF Score
Genscript Biotech Corp STU:G51
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genscript Biotech Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €532.9 Mil mean?
Genscript Biotech (STU:G51) has a Marketable Securities of €532.9 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Genscript Biotech and its competitors.
Is Genscript Biotech's Marketable Securities too high?
Genscript Biotech's current Marketable Securities is €532.9 Mil. Overall, Genscript Biotech has a GF Score™ of 77/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genscript Biotech's Marketable Securities compare to VRTX and REGN?
Genscript Biotech's Marketable Securities of €532.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Genscript Biotech and its competitors. Genscript Biotech's current Marketable Securities is €532.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genscript Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genscript Biotech (STU:G51) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.97, compared to a current price of €3.18 — trading 61.4% above its estimated fair value. The current Marketable Securities is €532.9 Mil. Genscript Biotech's overall GF Score™ is 77/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Genscript Biotech (STU:G51), the current Marketable Securities is €532.9 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genscript Biotech (STU:G51) Overvalued in 2026?

Based on GuruFocus' analysis, Genscript Biotech stock appears to be overvalued. The current stock price of €3.18 is trading 61.4% above its estimated GF Value™ of €1.97. GuruFocus considers Genscript Biotech to be Significantly Overvalued.

Key valuation signals for STU:G51:

  • Marketable Securities: €532.9 Mil
  • GF Value™: €1.97 vs. price of €3.18 (61.4% above fair value)
  • GF Score™: 77/100 with 8 warning signs

No single metric tells the full story. See the STU:G51 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genscript Biotech Business Description

Other Exchanges GNNSF:USA01548:Hong Kong
Address 860 Centennial Avenue, Piscataway, NJ, USA, 08854
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
77GF Score

Get the complete analysis for STU:G51

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.18
Price
€1.97
GF Value